The mTOR kinase inhibitors polarize glioma-activated microglia to express a M1 phenotype

Journal of Neuroinflammation

Volumn 11, Issue 1, 2014, Pages

  Lisi, Lucia ^a   Laudati, Emilia ^a   Navarra, Pierluigi ^a   Dello Russo, Cinzia ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; ALPHA INTERFERON; ARGINASE; ARGINASE I, RAT; BROXURIDINE; CULTURE MEDIUM; ENZYME INHIBITOR; LIPOPOLYSACCHARIDE; MESSENGER RNA; MTOR PROTEIN, HUMAN; NOS2 PROTEIN, MOUSE; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARG GENE; ARTICLE; CELL ACTIVATION; CELL POLARITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GENE; GLIOMA CELL; INTERLEUKIN 10 GENE; MICROGLIA; NONHUMAN; PROTEIN EXPRESSION; RAT; ANALYSIS OF VARIANCE; ANIMAL; BRAIN CORTEX; CELL CULTURE; CELL PROLIFERATION; CULTURE MEDIUM; CYTOLOGY; DRUG EFFECTS; GLIA; GLIOMA; METABOLISM; PATHOLOGY; PHARMACOLOGY; PHOSPHORYLATION; TIME;

ANALYSIS OF VARIANCE; ANIMALS; ARGINASE; BROMODEOXYURIDINE; CELL PROLIFERATION; CELLS, CULTURED; CEREBRAL CORTEX; CULTURE MEDIA, CONDITIONED; ENZYME INHIBITORS; GLIOMA; INTERFERON-ALPHA; LIPOPOLYSACCHARIDES; NEUROGLIA; NITRIC OXIDE SYNTHASE TYPE II; PHOSPHORYLATION; RATS; RNA, MESSENGER; TIME FACTORS; TOR SERINE-THREONINE KINASES;

EID: 84904522986     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-11-125     Document Type: Article

References (36)

1. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
2. Foster KG, Fingar DC. Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem 2010, 285:14071-14077.
3. Li J, Kim SG, Blenis J. Rapamycin: One Drug, Many Effects. Cell Metab 2014, 19:373-379.
4. Menon S, Manning BD. Common corruption of the mTOR signaling network in human tumors. Oncogene 2008, 27(Suppl 2):43-51.
5. Oh WJ, Jacinto E. mTOR complex 2 signaling and functions. Cell Cycle 2011, 10:2305-2316.
6. Rolle CE, Sengupta S, Lesniak MS. Mechanisms of immune evasion by gliomas. Adv Exp Med Biol 2012, 746:53-76.
7. Bradley D, Rees J. Updates in the management of high-grade glioma. J Neurol 2014, 261:651-654.
8. Grzmil M, Hemmings BA. Overcoming resistance to rapalogs in gliomas by combinatory therapies. Biochim Biophys Acta 2013, 1834:1371-1380.
9. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010, 363:1801-1811.
10. Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 2011, 10:868-880.
11. Cloughesy TF, Cavenee WK, Mischel PS. Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol 2014, 9:1-25.
12. Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 2011, 121:1231-1241.
13. Dello Russo C, Lisi L, Tringali G, Navarra P. Involvement of mTOR kinase in cytokine-dependent microglial activation and cell proliferation. Biochem Pharmacol 2009, 78:1242-1251.
14. Lisi L, Navarra P, Feinstein DL, Dello Russo C. The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes. J Neuroinflammation 2011, 8:1.
15. Dello Russo C, Lisi L, Feinstein DL, Navarra P. mTOR kinase, a key player in the regulation of glial functions: relevance for the therapy of multiple sclerosis. Glia 2013, 61:301-311.
16. da Fonseca AC, Badie B. Microglia and macrophages in malignant gliomas: recent discoveries and implications for promising therapies. Clin Dev Immunol 2013, 2013:264124.
17. Schwartz M, Butovsky O, Kipnis J. Does inflammation in an autoimmune disease differ from inflammation in neurodegenerative diseases? Possible implications for therapy. J Neuroimmune Pharmacol 2006, 1:4-10.
18. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002, 23:549-555.
19. Biswas SK, Allavena P, Mantovani A. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol 2013, 35:585-600.
20. Komohara Y, Ohnishi K, Kuratsu J, Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol 2008, 216:15-24.
21. Li W, Graeber MB. The molecular profile of microglia under the influence of glioma. Neuro Oncol 2012, 14:958-978.
22. Lisi L, Stigliano E, Lauriola L, Navarra P, Dello Russo C. Proinflammatory-activated glioma cells induce a switch in microglial polarization and activation status, from a predominant M2b phenotype to a mixture of M1 and M2a/b polarized cells. ASN Neuro 2014, 6:171-183.
23. Byles V, Covarrubias AJ, Ben-Sahra I, Lamming DW, Sabatini DM, Manning BD, Horng T. The TSC-mTOR pathway regulates macrophage polarization. Nat Commun 2013, 4:2834.
24. Rocher C, Singla DK. SMAD-PI3K-Akt-mTOR pathway mediates BMP-7 polarization of monocytes into M2 macrophages. PLoS One 2013, 8:e84009.
25. Mercalli A, Calavita I, Dugnani E, Citro A, Cantarelli E, Nano R, Melzi R, Maffi P, Secchi A, Sordi V, Piemonti L. Rapamycin unbalances the polarization of human macrophages to M1. Immunology 2013, 140:179-190.
26. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006, 22:159-168.
27. Dello Russo C, Boullerne AI, Gavrilyuk V, Feinstein DL. Inhibition of microglial inflammatory responses by norepinephrine: effects on nitric oxide and interleukin-1beta production. J Neuroinflammation 2004, 1:9.
28. Lisi L, Tramutola A, Navarra P, Dello Russo C. Antiretroviral agents increase NO production in gp120/IFNγ-stimulated cultures of rat microglia via an arginase-dependent mechanism. J Neuroimmunol 2014, 266:24-32.
29. Powell JD, Pollizzi KN, Heikamp EB, Horton MR. Regulation of immune responses by mTOR. Annu Rev Immunol 2012, 30:39-68.
30. Zhou H, Huang S. Role of mTOR signaling in tumor cell motility, invasion and metastasis. Curr Protein Pept Sci 2011, 12:30-42.
31. Masri J, Bernath A, Martin J, Jo OD, Vartanian R, Funk A, Gera J. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res 2007, 67:11712-11720.
32. Das G, Shiras A, Shanmuganandam K, Shastry P. Rictor regulates MMP-9 activity and invasion through Raf-1-MEK-ERK signaling pathway in glioma cells. Mol Carcinog 2011, 50:412-423.
33. Huysentruyt LC, Akgoc Z, Seyfried TN. Hypothesis: are neoplastic macrophages/microglia present in glioblastoma multiforme?. ASN Neuro 2011, 3:e00064.
34. Huysentruyt LC, Mukherjee P, Banerjee D, Shelton LM, Seyfried TN. Metastatic cancer cells with macrophage properties: evidence from a new murine tumor model. Int J Cancer 2008, 123:73-84.
35. Reynolds MM, Witzeling SD, Damodaran VB, Medeiros TN, Knodle RD, Edwards MA, Lookian PP, Brown MA. Applications for nitric oxide in halting proliferation of tumor cells. Biochem Biophys Res Commun 2013, 431:647-651.
36. Dheen ST, Kaur C, Ling EA. Microglial activation and its implications in the brain diseases. Curr Med Chem 2007, 14:1189-1197.